meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - HER2-positive
es-BC - HER2 negative - (neo)adjuvant (NA)
1
es-BC - HER2 positive - (neo)adjuvant (NA)
4
la/mBC - HER2 positive
la/mBC - HER2 positive - (neo)adjuvant (NA)
la/mBC - HER2 positive - 1st Line (L1)
5
la/mBC - HER2 positive - 2nd Line (L2)
13
HER inhibitor
HER2 inhibitor
pertuzumab based treatment
pertuzumab plus trastuzumab
pertuzumab plus trastuzumab plus docetaxel
trastuzumab based treatment
trastuzumab plus endocrine therapy
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab plus trastuzumab plus docetaxel
versus all
vs HER inhibitor
vs HER2 inhibitor
vs pertuzumab based treatment
vs pertuzumab plus trastuzumab plus cyclophosphamide
vs trastuzumab based treatment
vs trastuzumab
vs trastuzumab plus chemotherapy
vs trastuzumab plus docetaxel
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pertuzumab based treatment
pertuzumab plus trastuzumab
pertuzumab plus trastuzumab plus docetaxel
la/mBC - HER2 positive - 1st Line (L1)
5
Comparator:
vs trastuzumab;
vs trastuzumab plus docetaxel;
Risk of bias:
low;
some concerns;
high;
NA;